ArticleClinical case reports2026
Trastuzumab Deruxtecan-Induced Pneumonitis: Case Series.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate with proven efficacy in metastatic breast cancer, but interstitial lung disease (ILD) and drug-induced pneumonitis are potentially life-threatening toxicities. We retrospectively reviewed three patients with HER2-positive metastatic breast cancer treated with T-DXd at a tertiary hospital in Saudi Arabia who subsequently developed pneumonitis. Pneumonitis developed after 2-9 cycles of T-DXd, presenting with cough, dyspnea, and ground-glass opacities. All patients received corticosteroids and required permanent discontinuation. Early recognition and multidisciplinary management of T-DXd-induced pneumonitis are essential. Clinicians should monitor respiratory symptoms and apply timely corticosteroid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.